A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...
Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...
NASM's Understanding Weight Loss Medications offers fitness and wellness professionals comprehensive, evidence-based research, along with exercise, nutrition, and behavioral strategies to support ...
Zepbound (tirzepatide) is only available on prescription ... dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) drug. You inject the drug into your stomach, thigh ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
News Medical on MSN7d
Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugsObesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback